Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.30 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.30 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16181145 | 0.90 | AR (0.39) | ARCYP2C8CYP2C9CYP2C19SLC22A6 | |
| SCHEMBL10195373 | 0.89 | HTR2A (0.36) | ARHTR2ASLC6A4KCNH2CYP2C8 | |
| SCHEMBL10195181 | 0.88 | PDE4B (0.35) | ARMAOAMAOB | |
| SCHEMBL10195081 | 0.87 | MEN1 (0.31) | MAOAMAOBHTR2ASLC6A4KCNH2 | |
| SCHEMBL10195343 | 0.86 | ESRRA (0.38) | ARNPSR1CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL10195204 | 0.86 | AR (0.41) | ARHTR2ASLC6A4KCNH2 | |
| SCHEMBL10195077 | 0.86 | HTR2A (0.36) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL10195073 | 0.86 | MAPK14 (0.33) | — | |
| SCHEMBL10195223 | 0.85 | AR (0.39) | ARHTR2ASLC6A4KCNH2CYP2C8 | |
| SCHEMBL10195222 | 0.85 | SLC22A12 (0.35) | ARKCNH2SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387569-B1 | HERBCIDES | SYNGENTA LTD (GB) | 2016-06-15 | — | — | EP | disclosed |
| US-20140378305-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378305-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| US-8865623-B2 | Herbicidally active cyclic diones and derivatives thereof, processes for their preparation, compositions, and method of controlling weeds | SYNGENTA LIMITED (GB) | 2014-10-21 | — | — | US | disclosed |
| US-8865623-B2 | Herbicidally active cyclic diones and derivatives thereof, processes for their preparation, compositions, and method of controlling weeds | SYNGENTA LIMITED (GB) | 2014-10-21 | — | — | US | disclosed |
| US-20120021907-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021907-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010081755-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378305-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | AR 2889/4885MAOA 1359/4885MAOB 1215/4885 |
| US-20120021907-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | AR 3331/4885MAOA 2359/4885MAOB 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.